

RESEARCH

Open Access

Participation of MCP-induced protein 1 in lipopolysaccharide preconditioning-induced ischemic stroke tolerance by regulating the expression of proinflammatory cytokines

Jian Liang^{*}, Jing Wang, Yasser Saad, Logan Warble, Edilu Becerra and Pappachan E Kolattukudy

Abstract

Background: Lipopolysaccharide (LPS) preconditioning-induced neuroprotection is known to be related to suppression of the inflammatory response in the ischemic area. This study seeks to determine if monocyte chemotactic protein-induced protein 1 (MCPIP1), a recently identified CCCH Zn finger-containing protein, plays a role in focal brain ischemia and to elucidate the mechanisms of LPS-induced ischemic brain tolerance.

Methods: Transcription and expression of MCPIP1 gene was monitored by qRT-PCR and Western blot. Mouse microglia was prepared from cortices of C57BL/6 mouse brain and primary human microglia was acquired from Clonexpress, Inc. Wild type and MCPIP1 knockout mice were treated with LPS (0.2 mg/kg) 24 hours before brain ischemia induced by transient middle cerebral artery occlusion (MCAO). The infarct was measured by 2,3,5-triphenyltetrazolium chloride (TTC) staining.

Results: MCPIP1 protein and mRNA levels significantly increased in both mouse and human microglia and mouse brain undergoing LPS preconditioning. MCPIP1 mRNA level significantly increased in mice ipsilateral brain than that of contralateral side after MCAO. The mortality of MCPIP1 knockout mice was significantly higher than that of wild-type after MCAO. MCPIP1 deficiency caused significant increase in the infarct volume compared with wild type mice undergoing LPS preconditioning. MCPIP1 deficiency caused significant upregulation of proinflammatory cytokines in mouse brain. Furthermore, MCPIP1 deficiency increased c-Jun N terminal kinase (JNK) activation substantially. Inhibition of JNK signaling decreased the production of proinflammatory cytokines in MCPIP1 knock out mice after MCAO.

Conclusions: Our data indicate that absence of MCPIP1 exacerbates ischemic brain damage by upregulation of proinflammatory cytokines and that MCPIP1 participates in LPS-induced ischemic stroke tolerance.

Keywords: Ischemic stroke, lipopolysaccharide (LPS) preconditioning, monocyte chemotactic protein-induced protein 1 (MCPIP1), middle cerebral artery occlusion (MCAO), proinflammatory cytokines

Background

Stroke is the second leading cause of death and the most frequent cause of permanent disability worldwide [1]. Inflammatory mechanisms that are activated within hours after brain ischemia represent a key target of current translational ischemic stroke research [2]. It has been reported that the levels of proinflammatory

cytokines and chemokines are increased after focal ischemia. Chemokines are cytokines that have the ability to induce chemotaxis on neighboring cells, particularly those involved in inflammatory actions [3,4]. While some cytokines may offer protection, many cytokines and most chemokines have been shown to participate in the neuronal damage processes [4,5]. Upregulation of cerebral proinflammatory cytokines, activation of local microglia, astrocytes and systemic lymphocytes and

* Correspondence: jian.liang@ucf.edu
Burnett School of Biomedical Sciences, University of Central Florida College of Medicine, 4000 Central Florida Blvd. Orlando, FL 32816, USA

invasion of leukocyte in the brain contribute substantially to ischemic brain damage [6].

Published data have shown that lipopolysaccharide (LPS) preconditioning is a powerful neuroprotective phenomenon by which a sublethal injurious stimulus renders the brain resistant to a subsequent damaging ischemic insult [7-11]. LPS preconditioning-induced neuroprotection is related to the suppression of the inflammatory response in the ischemic area of the brain, but the mechanisms involved in LPS preconditioning are poorly understood [12,13].

MCPIP1 (also known as ZC3H12A) is a recently identified protein in human peripheral blood monocytes treated with monocyte chemotactic protein 1 (MCP-1) [14]. In our previous studies, MCPIP1 was shown to be a negative regulator of macrophage activation [15]. Further investigations by our group and others indicated that MCPIP1 can play a significant anti-inflammatory role by inhibiting the generation of a set of major proinflammatory cytokines [16,17]. MCPIP1 was also found to be inducibly expressed in monocytes, macrophages, and endothelial cells with LPS stimulation [13,17-19]. However, the role of MCPIP1 in ischemic stroke has not been examined. In this study we examined MCPIP1 gene expression in human and mouse microglia, and in mouse brain under LPS treatment or preconditioning. We also examined MCPIP1 gene expression in mouse brain undergoing MCAO. We studied whether there is loss of LPS preconditioning-induced ischemic stroke tolerance in MCPIP1 knockout mice and whether such effects involve regulation of expression of proinflammatory cytokines. Furthermore we investigated the effects of MCPIP1 on JNK signal pathway under brain ischemia conditions and the effects of JNK inhibitor on the production of proinflammatory cytokines in MCPIP1 knockout mice after brain ischemia. Our data indicate that MCPIP1 is upregulated under LPS preconditioning or after brain ischemia stress and MCPIP1 participates in LPS preconditioning-induced ischemic stroke tolerance by modulating gene expression of proinflammatory cytokines.

Methods

Animals and LPS preconditioning

MCPIP1 knockout mice were established as previously described [16]. Briefly, *Mcpip1*^{-/-} mice was generated by homologous recombination in embryonic stem cells from C57/BL6 background mice. Exons 3, 4, 5 and most part of 6 of mouse *Mcpip1* were targeted with a LacZ-neomycin cassette in embryonic stem cells established from C57/BL6 mice and established *Mcpip1*^{-/-} mice in pure C57/BL6 background. The deletion of MCPIP1 protein in *Mcpip1*^{-/-} mice was confirmed by Immunoblotting. Six to eight-week-old mice were used. All

experimental procedures were approved by the Institutional Animal Care and Use Committee of University of Central Florida. We performed all the experiments by using littermate mice. For in vivo study mice were given an intraperitoneal injection of saline or LPS (Sigma, USA) 0.2 mg/kg in saline 24 hours before transient middle cerebral artery occlusion (MCAO) [12].

Cell cultures

Human microglia was acquired from Clonexpress, Inc. (Gaithersburg, MD, USA) and cultured in 50:50 DMEM: F-12 supplemented with 10% FBS and 10 ng/ml of M-CSF, grown at 37°C in a humidified environment (5% CO₂; 95% air). Mouse microglia cultures were generated by the procedures described by Watson and colleagues [20]. In brief, mouse microglia was prepared from cortices of C57BL/6 mouse brain. Brain tissue was placed in 2 ml Dulbecco's modified Eagle's medium (DMEM; Invitrogen, USA) supplemented with 10% fetal bovine serum (Gibco, USA), penicillin (100 U/ml; Gibco, USA) and streptomycin (100 U/ml; Gibco, USA). Samples were triturated, passed through a sterile nylon mesh filter; centrifuged (1500 rpm, 5 min, 20-22°C) and the pellets were resuspended in DMEM. Cells were grown in T25 flasks in DMEM medium supplemented with 10% FBS. After 12 days the flasks were shaken for 2 hours at 110 rpm at room temperature and tapped several times to remove the non-adherent microglia. The supernatant was centrifuged at 1500 rpm for 5 min and the pellet was resuspended in normal DMEM medium mentioned above for experiments. LPS (Catalog #, L4516, Sigma, USA) or PBS was added to medium (0.1 µg/ml) for cell stimulus experiments.

Mouse focal brain ischemia reperfusion model

For focal brain ischemia, mouse reversible middle cerebral artery occlusion (MCAO) was produced by filament occlusion of the right MCA following a modification of the method reported by Clark and colleagues [21]. In brief, mice were anesthetized with isoflurane (induction with 3%; maintenance with 1.2%) in oxygen-enriched air by facemask, and rectal temperature was controlled at 37 ± 0.5°C throughout the experiment with heating lamps. Unilateral MCAO was performed by inserting a 7-0 nylon monofilament into the internal carotid artery via an external carotid artery stump and then positioning the filament tip for occlusion at a distance of 8-9 mm beyond the internal carotid/pterygopalatine artery bifurcation. MCA was occluded for 90 minutes followed by reperfusion.

Brain infarction measurement

The brains were stained with 2,3,5-triphenyltetrazolium chloride (TTC) (Sigma, USA) to determine infarct

volume [4,22]. After 90 min of MCAO and 48 hours of reperfusion, mice were anesthetized with 4% isoflurane and brains were removed and sectioned coronally at a thickness of 2 mm and incubated in 2% TTC at 37°C for 20 minutes. Brain slices were then fixed in 4% paraformaldehyde at 4°C overnight and scanned into a computer, and quantified using the Image J software. Infarct volume was expressed as a percentage of the contralateral hemisphere. There were 10 mice in each group.

Brain edema measurement

The mice were anesthetized with 4% isoflurane and brains were removed at different time points, i.e., 12, 24, and 48 h after MCAO. The brains were weighed to obtain the wet weight and were then dried at 105°C for 24 h before measuring dry weight. Brain moisture content (%) was calculated as follows, $100 \times (\text{wet weight} - \text{dry weight}) / \text{wet weight}$. There were ten mice in each group.

Quantitative real-time PCR

Quantitative Real Time-PCR was performed as previously described [15]. Briefly, Total RNA was isolated using RNA STAT-60 reagent (TEL-TEST, INC. USA), after removing the genomic DNA using DNase I (Ambion, USA), 2.0 ug of total RNA from microglia or mouse brain tissue was reverse-transcribed to cDNA using a commercially available kit (Applied Biosystems, USA). Quantitative real-time PCR was performed with iCycler Thermal Cycler (Bio-Rad, USA) using $2 \times$ SYBR Green master mixes (Bio-Rad, USA). Forty cycles were conducted as follows: 95°C for 30 s, 60°C for 30 s, proceeded by 10 min at 95°C for polymerase activation. Quantification was performed by the delta cycle time method, with mouse β -actin used for normalization. Human MCP1P1 gene specific primers (IDT, USA) were F: 5'-GCCGGCGGCCTTA; R: 5'-GCACTGCTCACTCTCTGTTAGCA. The mouse specific primers (IDT, USA) are as follows, MCP1P1: F: 5'-CCCCCTGACGACCCTTAG; R: 5'-GGCAGTGGTTTCTTACGAAGGA, TNF α : F: 5'-CTGAGGTCAATCTGCCCAAGTAC; R: 5'-CTTCACAGAGCAATGACTCCAAAG, IL-1 β : F: 5'-GCCCATCCTCTGTGACTCAT; R: 5'-AGGCCACAGGTATTTTGTGCG, IL-6: F: 5'-TCGTGGAAATGAGAAAAGAGTTG; R: 5'-AGTGCATCATCGTTGTTCATACA, MCP-1: F: 5'-CCATCTCTGACCTGCTCTTCCT; R: -AGACCCACTCATTTGCAGCAT, β -actin: F: 5'-AAATCGTGCGTGACATCAAAGA; R: 5'-GGCCATCTCCTGCTCGAA.

Western blot

Western blot was performed as previously described [15]. Proteins from microglia or mouse brain tissue were extracted and concentrations were determined by

the Bradford method (Bio-Rad, USA) with bovine serum albumin as the standard. Proteins (50 ug) were separated by SDS-PAGE and transferred onto nitrocellulose membranes in transfer buffer containing 0.1% SDS. The membranes were blocked with 5% nonfat dry milk in 0.05% Tween 20 in Tris-buffered saline (TTBS) for 2 h and incubated with the primary antibodies against MCP1P1 (Catalog #, sc136750, Santa Cruz, USA), phospho-SAPK/JNK (Catalog #, 9251, Cell Signaling, USA), SAPK/JNK (Catalog #, 9252, Cell Signaling, USA), phospho-c-jun (Catalog #, 2361, Cell Signaling, USA), c-jun (Catalog #, 2315, Cell Signaling, USA) at a 1:1000 dilution in the blocking buffer, 4°C, gently shaking, overnight. After being washed with TTBS three times for 10 min each, the membranes were incubated with a 1:2,000 dilution of secondary antibody (Santa Cruz, USA) in TTBS for 1 h. Following three 10-min washes with TTBS, membranes were incubated with SuperSignal West Pico Chemiluminescent Substrate (Pierce, USA) and exposed to x-ray film. The intensity of bands was quantified by AlphaImage 2200 (AlphaInnotech, USA). The ratios between interested protein bands and the loading control (β -actin, total JNK or c-jun) were calculated and the data are expressed as the normalized folds with respect to sham.

Drug administration

JNK specific inhibitor SP600125 (Sigma, USA) was dissolved in PPCEs vehicle (30% polyethylene glycol-400/20% polypropylene glycol/15% cremophor EL/5% ethanol/30% saline) as reported [23] and was treated by mice tail-vein injection 1 h before ischemia at a dose of 15 mg/kg.


Statistical analysis

The data are presented as mean \pm SD. Multiple comparisons were evaluated by one-way ANOVA followed by the Tukey or Dunnett test. Two-group comparisons were analyzed by the 2-tailed Student t test. For all analyses, a value of $P < 0.05$ was considered significant.

Results

MCPIP1 induction in mouse and human microglia by LPS treatment

In ischemic stroke, microglia is activated after brain ischemia and release inflammatory cytokines that exacerbate brain injury. We examined whether LPS induces MCP1P1 in mouse microglia. The MCP1P1 mRNA level in mouse microglia was significantly induced by LPS (0.1 μ g/ml) treatment compared to PBS controls; significant increase of MCP1P1 in transcript level was detected at 3 h and reached 11.12 ± 1.63 fold at 24 h after LPS treatment ($P < 0.001$; Figure 1A). Consistently, the MCP1P1 protein levels in mouse microglia




were significantly higher in LPS (0.1 $\mu\text{g/ml}$) treated cells than in the controls, 5.93 ± 0.72 fold on 24 h after LPS treatment ($P < 0.05$; Figure 1B). The MCPIP1 mRNA level in human microglia was significantly higher in the LPS (0.1 $\mu\text{g/ml}$) group than that in the controls at 24 h after LPS treatment (9.35 ± 1.76 folds, $P < 0.001$; Figure 2A). The MCPIP1 protein level in human microglia was

also significantly higher in LPS (0.1 $\mu\text{g/ml}$) group than that of control (5.65 ± 1.23 folds, $P < 0.01$; Figure 2B).

MCPIP1 induction in mouse brain cortex after LPS preconditioning

To determine whether MCPIP1 expression is induced by LPS preconditioning in vivo, mice were treated



systemically with 0.2 mg/kg LPS in saline and control mice with only saline as reported [12]. MCPIP1 mRNA levels significantly increased in the brain cortex as a result of LPS treatment. After 3 hr of LPS treatment the transcript levels showed substantial increase (3.81 ± 0.53 folds) and the maximal level was reached 24 hr (8.62 ± 1.51 folds) after LPS administration with subsequent decrease but remaining at 3.27 ± 0.59 folds level even after 7 days (Figure 1C). MCPIP1 protein levels significantly increased in the 24-hours after LPS treatment (5.23 ± 0.82 folds) and showed further increase until 7 days (Figure 1D). These results suggest that MCPIP1 is significantly elevated in the mouse brain by LPS preconditioning treatments.

MCPIP1 induction in mouse brain cortex after MCAO

We determined whether MCPIP1 is induced by brain ischemia stress. We examined MCPIP1 mRNA level in mouse brain cortex after MCAO. The MCPIP1 mRNA level in the ipsilateral side of mouse brain was significantly induced after MCAO compared to the contralateral side; significant increase of MCPIP1 in transcript level was detected at 3 h and reached 9.85 ± 2.1 fold at 24 h after MCAO ($P < 0.01$; Figure 3), suggesting that MCPIP1 may play an important role after brain ischemia stress.

Loss of LPS-induced tolerance to ischemic stroke by MCPIP1 deficiency

We examined the effects of low dose (0.2 mg/kg) of LPS on ischemic brain infarction and the results showed that

the infarct size of LPS-preconditioned mice was significantly reduced compared to that of saline control. ($41.5 \pm 10.1\%$ versus $26.3 \pm 6.4\%$, Figure 4A, B). To determine whether MCPIP1 is involved in LPS preconditioning-induced tolerance to ischemic brain injury, MCPIP1 knock out or wild type mice were treated with a low dose of LPS (0.2 mg/kg), and 24 hours later these mice were subjected with MCAO for 90 min followed by 48 hours reperfusion. The brain infarct size was assessed with TTC staining 48 hours after MCAO. MCPIP1 knockout mice failed to evoke LPS-induced tolerance compared with that of wild type ($65.6 \pm 12.1\%$ versus $26.3 \pm 6.4\%$, Figure 4A, B). There was no significant difference in brain infarct between LPS-preconditioning and control in MCPIP1 knockout mice.

Brain edema and mortality associated with ischemia/reperfusion (I/R) injury are exacerbated by absence of MCPIP1

To investigate the possible role of MCPIP in ischemic injury in the brain we subjected MCPIP1 knockout mice to reversible middle cerebral artery occlusion (MCAO) for 90 minutes followed by reperfusion for 72 hours. Edema is one of the earliest pathological changes after ischemic neuronal damage, which significantly increases as early as 20 to 45 mins after MCAO [24]. Our results show that brain edema was enhanced in a time-dependent manner after MCAO in wild type mice (6 h: $81.31 \pm 0.19\%$; 24 h: $82.78 \pm 0.23\%$; 48 h: $85.34 \pm 0.33\%$, Figure 5B) as compared with the sham-treated group (48 h:





Figure 3 MCPIP1 mRNA increases in ipsilateral brain after MCAO. MCPIP1 mRNA expression in mouse brain was determined at 3 h, 6 h and 24 h after MCAO by qRT-PCR. Values represent mean \pm SD, * $p < 0.05$, # $p < 0.01$ versus contralateral control. $n = 5$ per group.



79.47 \pm 0.21%). However, MCPIP1 knockout mice showed a significantly higher increase in brain edema after MCAO (6 h: 83.52 \pm 0.27%; 24 h: 85.73 \pm 0.31%; 48 h: 88.69 \pm 0.38%, Figure 5B). MCPIP1 knockout mice showed significantly lower survival than the wild type and sham-operated MCPIP1 knockout mice ($p < 0.05$, Figure 5A).


Increased proinflammatory cytokine expression


We examined the expression of proinflammatory cytokine transcript in the ischemic brain of the wild type and MCPIP1 knockout mice after MCAO. TNF α , IL-1 β ,

IL-6 and MCP-1 expression was substantially upregulated after brain ischemia. Different cytokines showed similar temporal pattern of this upregulation. These cytokines were more highly induced in MCPIP1 knockout mice compared with that of wild type 6 h, 12 h and 24 h after MCAO (Figure 6).

Activation of c-jun N terminal kinase (JNK) signaling pathway

JNK/c-jun signaling mediates a wide spectrum of cellular responses, including infection, inflammation, and apoptosis [25]. To understand the mechanisms





underlying the increased inflammatory response of MCPIP1 knockout mice after brain ischemia, we examined the activation of JNK/c-jun signaling pathway. The phosphorylation of JNK and c-jun significantly increased in mice after brain ischemia/reperfusion and absence of MCPIP1 caused marked elevation in the levels of both JNK and c-jun phosphorylation after ischemia/reperfusion compared with that of wild type (Figure 7A, B, C, D).


Knocking out MCPIP1 increases proinflammatory cytokines via JNK signaling cascade

We determined whether the increased proinflammatory cytokine production is mediated via JNK and c-jun signaling pathway. We performed specific JNK inhibition experiments in vivo with JNK inhibitor SP600125 in MCPIP1 knock out mice after MCAO. MCPIP1 knock out mice received the JNK inhibitor SP600125 (15 mg/kg) before 60 min of transient focal ischemia. SP600125 treatment caused a significant decrease in the levels of both JNK and c-jun phosphorylation (Figure 8A, B, C, D) and the expression of proinflammatory cytokines

measured at 12 h and 24 h after MCAO compared with vehicle group (Figure 8E). These results support the hypothesis that activation of JNK signaling may be an integral component of the mechanism underlying the excessive generation of proinflammatory cytokines after ischemic brain injury.

Discussion

It is becoming increasingly clear that inflammation and innate immune response play an important role in the brain injury after ischemic stroke [26,27]. Inflammatory mechanisms that are activated within hours after brain ischemia represent a key target for stroke intervention. Although it has been known that LPS preconditioning can induce significant tolerance to ischemic brain injury and inhibit inflammatory responses such as activation of microglia, brain neutrophil infiltration and proinflammatory cytokine generation, the molecular mechanisms that contribute to brain ischemia tolerance by LPS preconditioning are not well-understood. The present study is the first to examine the role of MCPIP1 in acute




cerebral ischemia. We found that MCPIP1 can be significantly induced in human and mouse microglia and mouse brain with LPS stimulus or preconditioning and that MCPIP1 gene expression significantly increased in mouse brain after MCAO. These findings are consistent with the significance of inflammatory processes contributing to the brain damage in ischemic stroke [26] and the anti-inflammatory properties of MCPIP1 [16,17]. Similarly we also found the upregulation of MCPIP1 in cultured mice astrocytes following LPS stimulation (data not shown) and activated astrocytes also play an important role in neuroinflammation [28]. Thus, we conclude that MCPIP1 is involved in LPS preconditioning-induced ischemic stroke tolerance by its anti-inflammatory activities and MCPIP1 may play an important role against ischemic brain injury. Consistent with other reports [7,12] we found that a small dose of LPS given systemically confers protection against ischemia in mouse brain with respect to infarct volume. More interestingly, we found that there was loss of LPS-induced ischemic stroke tolerance by MCPIP1 deficiency. There was much larger ischemic brain infarct area in MCPIP1 deficient mice compared to the wild type. Higher mortality in MCPIP1 knockout mice subjected to focal brain ischemia/reperfusion injury compared with wild type indicated that MCPIP1 deficient mice is more sensitive

to ischemic brain injury than wild type. This result was not due to the possible general physiological weakness of MCPIP1 knockout mice to resist stress of surgery as mortality of sham group of MCPIP1 knockout mice was much less than the animals subjected to ischemic injury.

Clinical data showed that the principal cause of stroke death in patients with malignant middle cerebral artery infarction was focal brain edema [29]. Experimental models of cerebral infarction show an increase in water content beginning within hours and peaking at 48 hours [30]. Progressive postischemic edema would result in increased intracranial pressure with compression of the brain stem, occlusive hydrocephalus and secondary ischemic damage finally followed by clinical deterioration, coma, and death within 2 to 5 days after stroke [31,32]. In this study, our data showed that absence of MCPIP1 significantly increased the infarct volume and brain edema compared to wild type after ischemia/reperfusion injury. Thus, severe brain edema may be the major cause of higher mortality in MCPIP1 knockout mice subjected to ischemic stroke.

Inflammatory response after stroke significantly contributes to ischemic brain damage, which can be subdivided into the cellular response and the cytokine response [6]. Neutrophils accumulate in the brain as early as 30 min after permanent middle cerebral artery



occlusion (MCAO). Transmigration is mediated by cell adhesion molecules such as vascular cell adhesion molecule (VCAM)-1, intercellular adhesion molecule (ICAM)-1, and selectin, which contribute to the recruitment of inflammatory cells to endothelial blood vessel wall [33,34]. When adhered to cerebral blood vessel walls, neutrophils transmigrate into the cerebral parenchyma, which can cause tissue damage by releasing reactive oxygen species and proteolytic enzymes. MCP1P1 expression is induced in human blood endothelial cells and overexpression of MCP1P1 suppresses cytokine-induced expression of VCAM-1, as well as monocyte adhesion to human endothelial cells [19]. Such properties of MCP1P1 helps to explain the present results that absence of MCP1P1 exacerbates ischemia induced brain injury.

Proinflammatory cytokines and chemokines contribute to stroke-related brain injury [6,35]. During ischemia,

cytokines, such as TNF- α , IL-1 β , IL-6, and chemokines such as CINC and MCP-1 are produced by a variety of activated cell types, including endothelial cells, microglia, astrocytes and neurons [36]. The deleterious effects of these cytokines include fever, arachidonic acid release, enhancement of NMDA mediated excitotoxicity, and stimulation of nitric oxide synthesis. TNF α and IL-1 have been shown to cause up-regulation of E-selectin, ICAM-1, ICAM-2, and VCAM-1 on cerebral endothelial cells and the induction of such adhesion molecules may explain the elevation of TNF α and IL-1 levels after ischemia increases neutrophil infiltration [37]. Additionally TNF α can stimulate acute-phase protein production, including plasminogen, disrupt the blood-brain barrier and stimulate the induction of other inflammatory mediators. LPS preconditioning can induce significant tolerance to ischemic brain injury and inhibit inflammatory responses such as activation of microglia,

brain neutrophil infiltration and proinflammatory cytokine generation. Some studies attributed LPS preconditioning to reprogramming of cellular response to ischemia via genomic changes that render the brain refractory to ischemic injury [11,38]. However, the molecular mechanisms that mediate the beneficial effects in LPS-induced ischemic tolerance remains poorly understood. In this study we observed that knocking out MCP1P1 increased the brain damage after ischemic stroke and significantly enhanced the expression of proinflammatory cytokines in the brain, which may account for the severe brain damage resulting from ischemia in MCP1P1 deficient mice. It has been established that endotoxin-preconditioning by LPS, TNF α and IL-1 β can induce ischemic tolerance. Less well studied is what mediates such beneficial tolerance in preconditioning process i.e. the necessary intermediate links for completion of preconditioning tolerance. If this link is lost, the chain from cytokines to tolerance would be broken; in other words, even if cytokines still exist the tolerance would be not induced or would be inhibited. We hypothesized that MCP1P1 is such an inducible factor or link which mediates, at least in part, the translation from cytokine stimulation to tolerance. When MCP1P1 is deficient, tolerance is reduced even in the presence of more cytokines, as the key mediator is missing. Our results suggest that MCP1P1 is such a mediating factor and MCP1P1-deficiency results in the loss of LPS-induced ischemia tolerance in the brain and higher level of proinflammatory cytokines in ischemic brain. How does MCP1P1 regulate these inflammatory cytokine responses remains to be fully elucidated. It has been reported that MCP1P1 might be functioning as an RNase to promote the degradation of some inflammatory mRNA such as IL-6 and IL-1 β [17]. We have found that MCP1P1 can also act as a deubiquitinase to negatively regulate JNK and NF- κ B signaling by targeting TNF receptor-associated factors (TRAFs) [16,39], which suggests that MCP1P1 may control inflammatory response by multiple mechanisms. Activation of JNK signaling pathways leads to c-Jun mediated inflammatory cytokine production [24,40,41]. In this study we found that knocking out MCP1P1 significantly enhanced the activation of JNK kinase and phosphorylation of c-jun in mouse brain after ischemic/reperfusion injury and that administration of the JNK inhibitor SP600125 reduced hyperphosphorylation of JNK and c-Jun signaling after cerebral ischemia and significantly decreased the production of proinflammatory cytokines such as TNF α and IL-1 β . Our study suggests that increased activation of JNK signaling pathway in MCP1P1 knockout mice leads to increased proinflammatory cytokine production.

Conclusions

Based on the data, we concluded that MCP1P1 participates in LPS preconditioning-induced ischemic stroke tolerance. Knocking out MCP1P1 gene exacerbates brain damage after cerebral ischemia/reperfusion by upregulation of proinflammatory cytokines.

Acknowledgements

This work was supported by James & Ester King Biomedical Research Grant 08KN-03 (to J. Liang) and National Institutes of Health grant HL69458 (to P.E. Kolattukudy).

Authors' contributions

JL designed the experiments, performed all experiments, analyzed the data, generated the figures, and wrote the manuscript. JW did parts of the animal surgery. JW, YS, LW, EB performed the experiments. PEK provided advice in the design of the study and in interpreting of data and critically read and corrected the manuscript. All authors have read and approved the manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 10 August 2011 Accepted: 24 December 2011

Published: 24 December 2011

References

1. Donnan GA, Fisher M, Macleod M, Davis SM: **Stroke**. *Lancet* 2008, **371**:1612-1623.
2. Liesz A, Suri-Payer E, Veltkamp C, Doerr H, Sommer C, Rivest S, Giese T, Veltkamp R: **Regulatory T cells are key cerebroprotective immunomodulators in acute experimental stroke**. *Nat Med* 2009, **15**:192-199.
3. Minami M, Katayama T, Satoh M: **Brain cytokines and chemokines: roles in ischemic injury and pain**. *J Pharmacol Sci* 2006, **100**:461-470.
4. Haines BA, Mehta SL, Pratt SM, Warden CH, Li PA: **Deletion of mitochondrial uncoupling protein-2 increases ischemic brain damage after transient focal ischemia by altering gene expression patterns and enhancing inflammatory cytokines**. *J Cereb Blood Flow Metab* 2010, **30**:1825-1833.
5. Beech JS, Reckless J, Mosedale DE, Grainger DJ, Williams SC, Menon DK: **Neuroprotection in ischemia-reperfusion injury: an antiinflammatory approach using a novel broad-spectrum chemokine inhibitor**. *J Cereb Blood Flow Metab* 2001, **21**:683-689.
6. Doyle KP, Simon RP, Stenzel-Poore MP: **Mechanisms of ischemic brain damage**. *Neuropharmacology* 2008, **55**:310-318.
7. Tasaki K, Ruetzler CA, Ohtsuki T, Martin D, Nawashiro H, Hallenbeck JM: **Lipopolysaccharide pre-treatment induces resistance against subsequent focal cerebral ischemic damage in spontaneously hypertensive rats**. *Brain Res* 1997, **748**:267-270.
8. Karikó K, Weissman D, Welsh FA: **Inhibition of toll-like receptor and cytokine signaling—a unifying theme in ischemic tolerance**. *J Cereb Blood Flow Metab* 2004, **24**:1288-1304.
9. Wang X, Hagberg H, Nie C, Zhu C, Ikeda T, Mallard C: **Dual role of intrauterine immune challenge on neonatal and adult brain vulnerability to hypoxia-ischemia**. *J Neuropathol Exp Neurol* 2007, **66**:552-561.
10. Orio M, Kunz A, Kawano T, Anrather J, Zhou P, Iadecola C: **Lipopolysaccharide induces early tolerance to excitotoxicity via nitric oxide and cGMP**. *Stroke* 2007, **38**:2812-2817.
11. Rosenzweig HL, Minami M, Lessov NS, Coste SC, Stevens SL, Henshall DC, Meller R, Simon RP, Stenzel-Poore MP: **Endotoxin preconditioning protects against the cytotoxic effects of TNF α after stroke: a novel role for TNF α in LPS-ischemic tolerance**. *J Cereb Blood Flow Metab* 2007, **27**:1663-1674.
12. Rosenzweig HL, Lessov NS, Henshall DC, Minami M, Simon RP, Stenzel-Poore MP: **Endotoxin preconditioning prevents cellular inflammatory response during ischemic neuroprotection in mice**. *Stroke* 2004, **35**:2576-2581.

13. Stevens SL, Leung PY, Vartanian KB, Gopalan B, Yang T, Simon RP, Stenzel-Poore MP: **Multiple preconditioning paradigms converge on interferon regulatory factor-dependent signaling to promote tolerance to ischemic brain injury.** *J Neurosci* 2011, **31**:8456-8463.
14. Zhou L, Azfer A, Niu J, Graham S, Choudhury M, Adamski FM, Younce C, Binkley PF, Kolattukudy PE: **Monocyte chemoattractant protein-1 induces a novel transcription factor that causes cardiac myocyte apoptosis and ventricular dysfunction.** *Circ Res* 2006, **98**:1177-1185.
15. Liang J, Wang J, Azfer A, Song W, Tromp G, Kolattukudy PE, Fu M: **A novel C/EBP β -zinc finger protein family regulates proinflammatory activation of macrophages.** *J Biol Chem* 2008, **283**:6337-6346.
16. Liang J, Saad Y, Lei T, Wang J, Qi D, Yang Q, Kolattukudy PE, Fu M: **MCP-1-induced protein 1 deubiquitinates TRAF proteins and negatively regulates JNK and NF- κ B signaling.** *J Exp Med* 2010, **207**:2959-2973.
17. Matsushita K, Takeuchi O, Standley DM, Kumagai Y, Kawagoe T, Miyake T, Satoh T, Kato H, Tsujimura T, Nakamura H, Akira S: **Zc3h12a is an RNase essential for controlling immune responses by regulating mRNA decay.** *Nature* 2009, **458**:1185-1190.
18. Liang J, Song W, Tromp G, Kolattukudy PE, Fu M: **Genome-wide survey and expression profiling of C/EBP β -zinc finger family reveals a functional module in macrophage activation.** *PLoS ONE* 2008, **3**:e2880.
19. Qi Y, Liang J, She ZG, Cai Y, Wang J, Lei T, Stallcup WB, Fu M: **MCP-1-induced protein 1 suppresses TNF α -induced VCAM-1 expression in human endothelial cells.** *FEBS Lett* 2010, **584**:3065-3072.
20. Watson MB, Costello DA, Carney DG, McQuillan K, Lynch MA: **SIGIRR modulates the inflammatory response in the brain.** *Brain Behav Immun* 2010, **24**:985-995.
21. Clark WM, Rinker LG, Lessov NS, Lowery SL, Cipolla MJ: **Efficacy of antioxidant therapies in transient focal ischemia in mice.** *Stroke* 2001, **32**:1000-1004.
22. Chen ZB, Huang DQ, Niu FN, Zhang X, Li EG, Xu Y: **Human urinary kallidinogenase suppresses cerebral inflammation in experimental stroke and downregulates nuclear factor- κ B.** *J Cereb Blood Flow Metab* 2010, **30**:1356-1365.
23. Zhang QG, Wang R, Khan M, Mahesh V, Brann DW: **Role of Dickkopf-1, an antagonist of the Wnt/ β -catenin signaling pathway, in estrogen-induced neuroprotection and attenuation of tau phosphorylation.** *J Neurosci* 2008, **28**:8430-8441.
24. Gerriets T, Walberer M, Ritschel N, Tschernatsch M, Mueller C, Bachmann G, Schoenburg M, Kaps M, Nedelmann M: **Edema formation in the hyperacute phase of ischemic stroke.** *J Neurosurg* 2009, **111**:1036-1042.
25. Muzio M, Natoli G, Sacconi S, Levrero M, Mantovani A: **The human toll signaling pathway: divergence of nuclear factor κ B and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6).** *J Exp Med* 1998, **187**:2097-101.
26. Lo EH: **T time in the brain.** *Nat Med* 2009, **15**:844-846.
27. Moskowitz MA, Lo EH, Iadecola C: **The science of stroke: mechanisms in search of treatments.** *Neuron* 2010, **67**:181-198.
28. Bellini MJ, Hereñú CB, Goya RG, Garcia-Segura LM: **Insulin-like growth factor-I gene delivery to astrocytes reduces their inflammatory response to lipopolysaccharide.** *J Neuroinflammation* 2011, **8**:21.
29. Harscher S, Reichart R, Terborg C, Hagemann G, Kalff R, Witte OW: **Outcome after decompressive craniectomy in patients with severe ischemic stroke.** *Acta Neurochir (Wien)* 2006, **148**:31-37.
30. Silver FL, Norris JW, Lewis AJ, Hachinski VC: **Early mortality following stroke: a prospective review.** *Stroke* 1984, **15**:492-496.
31. Ropper AH, Shafran B: **Brain edema after stroke: clinical syndrome and intracranial pressure.** *Arch Neurol* 1984, **1**:26-29.
32. Frank JL: **Large hemispheric infarction, deterioration, and intracranial pressure.** *Neurology* 1995, **7**:1286-1290.
33. Hansson GK, Libby P: **The immune response in atherosclerosis: a double-edged sword.** *Na Rev Immunol* 2006, **6**:508-519.
34. You B, Jiang YY, Chen S, Yan G, Sun J: **The orphan nuclear receptor Nur77 suppresses endothelial cell activation through induction of IkappaB α expression.** *Cir Res* 2009, **104**:742-749.
35. Gong C, Qin Z: **Cellular localization of tumor necrosis factor α following focal cerebral ischemia in mice.** *Brain Research* 1998, **801**:1-8.
36. Huang J, Upadhyay U, Tamargo RJ: **Inflammation in stroke and focal cerebral ischemia.** *Surgical Neurology* 2006, **66**:232-245.
37. Yamasaki Y, Matsuo Y: **New therapeutic possibility of blocking cytokine-induced neutrophil chemoattractant on transient ischemic brain damage in rats.** *Brain Research* 1997, **759**:103-111.
38. Marsh B, Stevens SL, Packard AE, Gopalan B, Hunter B, Leung PY, Harrington CA, Stenzel-Poore MP: **Systemic lipopolysaccharide protects the brain from ischemic injury by reprogramming the response of the brain to stroke: a critical role for IRF3.** *J Neurosci* 2009, **29**:9839-9849.
39. Niu J, Wang K, Graham S, Azfer A, Kolattukudy PE: **MCP-1-induced protein attenuates endotoxin-induced myocardial dysfunction by suppressing cardiac NF- κ B activation via inhibition of I κ B kinase activation.** *J Mol Cell Cardiol* 2011.
40. Borsello T, Clarke PG, Hirt L, Vercelli A, Repici M, Schorderet DF, Bogousslavsky J, Bonny C: **A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia.** *Nat Med* 2003, **9**:1180-1186.
41. Wellen KE, Hotamisligil GS: **Inflammation, stress, and diabetes.** *J Clin Invest* 2005, **115**:1111-1119.

doi:10.1186/1742-2094-8-182

Cite this article as: Liang *et al.*: Participation of MCP-induced protein 1 in lipopolysaccharide preconditioning-induced ischemic stroke tolerance by regulating the expression of proinflammatory cytokines. *Journal of Neuroinflammation* 2011 **8**:182.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

